SAN FRANCISCO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data ...

Edwards Lifesciences Corp.’s Sapien 3 platform has been approved for a new indication. The Food and Drug Administration recently cleared the line of catheter-based heart valves, which includes Sapien ...

Edwards Lifesciences’ transcatheter aortic valve replacement (TAVR) system has demonstrated positive results in a long-term trial readout, as global demand for the technology increases. The company ...

IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences Corporation (EW) today announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of ...

One-year outcomes in the ENCIRCLE trial’s main cohort (299 patients unsuitable for other treatment options) achieved low rates for death and low heart failure hospitalization for patients treated with ...

Edwards Lifesciences had a monumental Q4 and full year 2025, growing sales 13.3% to $1.57 billion in the last quarter of the year. The company’s TAVR and TMTT performance are largely being credited ...

The U.S. FDA noted in a series of Federal Register declarations that several device makers are working with the Patent and Trademark Office to claim regulatory review times for their devices, ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...